FAQ on Quantum BioPharma Ltd.'s Submission of MS Drug Candidate to UK ILAP Program
Summary
Quantum BioPharma Ltd. has submitted its multiple sclerosis drug candidate, Lucid-MS, to the UK's ILAP program to accelerate its development and approval, marking a significant step in its global strategy to enhance patient access to innovative treatments.
What is Quantum BioPharma Ltd.’s recent announcement about?
Quantum BioPharma Ltd. announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has submitted its multiple sclerosis drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program to accelerate its development and approval.
Why is the submission to the UK’s ILAP program significant?
The submission to the UK’s ILAP program is significant because it aims to accelerate access to groundbreaking treatments by streamlining the drug development and approval process, uniting developers, regulators, and the NHS.
What is Lucid-MS?
Lucid-MS is a first-in-class therapy developed by Quantum BioPharma Ltd. targeting demyelination in multiple sclerosis, shown to prevent and reverse myelin degradation in preclinical models.
How does this submission support Quantum BioPharma’s strategy?
This submission supports Quantum BioPharma’s global strategy to speed clinical advancement and patient access to Lucid-MS through strategic regulatory pathways like the UK’s ILAP program.
Where can I find more information about Quantum BioPharma Ltd.?
More information about Quantum BioPharma Ltd. is available in the company’s newsroom at https://ibn.fm/QNTM and through its subsidiary’s website at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/.
What other products or investments does Quantum BioPharma have?
Quantum BioPharma has developed UNBUZZD(TM), an OTC product, and retains ownership of 25.71% of Celly Nutrition Corp. It also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc.
What are the terms of the agreement between Quantum BioPharma and Celly Nutrition Corp.?
The agreement includes royalty payments of 7% of sales from unbuzzd(TM) to Quantum BioPharma until payments total $250 million, after which the royalty drops to 3% in perpetuity, with Quantum retaining rights to develop similar products for pharmaceutical and medical uses.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99200